Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater
- 1 February 1996
- journal article
- Published by Wolters Kluwer Health in Pain
- Vol. 64 (2) , 315-322
- https://doi.org/10.1016/0304-3959(95)00106-9
Abstract
In addition to their potent vasoconstrictor properties, the endothelins (endothelin-1 and -3) may possess neurotransmitter/neuromediator and neuroendocrine actions. The aim of the present study was to evaluate the role of endothelins (ET) in mediating neurogenic inflammation of cephalic tissues in the rat. For this purpose, bosentan, a specific non-peptide mixed antagonist of ET receptors, was tested in rat models of neurogenic and non-neurogenic plasma extravasation in the dura mater and extracranial tissues (eyelid, conjunctiva, lip, tongue). Bosentan was effective for preventing neurogenic inflammation in the dura mater induced by unilateral electrical stimulation of the trigeminal ganglion or intravenous injection of capsaicin, whereas it was ineffective in extracranial tissues or after injection of substance P (non-neurogenic inflammation). The effect of nerve fiber stimulation on ET plasma concentrations in superior sagittal sinus was measured using selective radioimmunoassays for ET-1 and -3. Endothelin-3 concentration significantly increased after intravenous injection of capsaicin, whereas ET-1 levels remained unchanged. Competition binding assays on microsomal membranes from the trigeminal ganglion revealed a single class of binding sites with equal affinity for ET-1 and ET-3, suggesting a homogenous population of ETB receptors. The role of ETB receptors in mediating inflammation was evidenced by the lack of efficacy of a selective ETA receptor antagonist, in contrast to the full efficacy of a selective ETB receptor antagonist, for preventing neurogenic inflammation induced by unilateral stimulation of the trigeminal ganglion. The role of ETB receptors was finally confirmed by the observation that exogenous administration of the ETB receptor agonist sarafotoxin S6c also induced plasma protein extravasation in the dura mater. This extravasation was not a direct effect of ETB receptor stimulation, because it was inhibited by spantide, a selective tachykinin receptor antagonist. These data strongly suggest that ET, acting through ETB receptors, may play an important role in mediating neurogenic inflammation in the meninges of rats. Since the profile of activity of bosentan is similar to that of the Symbol agonists, sumatriptan and ergot alkaloios, one may speculate that ET receptor antagonists might be potentially effective in the treatment of acute migraine attacks.Keywords
This publication has 42 references indexed in Scilit:
- Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neuronsCell, 1994
- Endothelin-1 enhances capsaicin-induced peptide release and cGMP accumulation in cultures of rat sensory neuronsNeuroscience Letters, 1994
- In vitro characterization of Ro 46‐2005, a novel synthetic non‐peptide endothelin antagonist of ETA and ETB receptorsFEBS Letters, 1993
- Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonistNature, 1993
- Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglionNeuropharmacology, 1991
- Further characterization of the putative 5‐HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura materBritish Journal of Pharmacology, 1991
- Sensory neuron-specific actions of capsaicin: mechanisms and applicationsTrends in Pharmacological Sciences, 1990
- Release of Substance P from Rat Hypothalamus and Pituitary by EndothelinEndocrinology, 1990
- The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura materBritish Journal of Pharmacology, 1990
- Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura materEuropean Journal of Pharmacology, 1989